BackY-Mabs Therapeutics Overview

Y-Mabs Therapeutics Other Current Liabilities

Track Y-Mabs Therapeutics's other current liabilities ($15M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$14.89M
↓ 54.10% YoYΔ $-17.55M vs prior year quarter

Peer average

Loading

Y-Mabs Therapeutics Other Current Liabilities History

Loading

Y-Mabs Therapeutics vs. peers: Other Current Liabilities Comparison

Loading

Y-Mabs Therapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Y-Mabs Therapeutics (YMAB) FAQ

As of the most recent data (June 2025), YMAB shows a other current liabilities of $15M. That compares with $32M in the prior-year period — down 54.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, YMAB's other current liabilities is now $15M (was $32M) — a 54.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Y-Mabs Therapeutics is outperforming or lagging.

Tracking YMAB's other current liabilities over time shows whether Y-Mabs Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $15M That compares with $32M in the prior-year period — down 54.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Y-Mabs Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $15M) with ownership activity and broader fundamentals.

Y-Mabs Therapeutics's other current liabilities is $15M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.